| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | P15; MTS2; TP15; CDK4I; INK4B; p15INK4b |
| WB Predicted band size | 15 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CDKN2B |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CDKN2B抗体的参考文献示例(仅供参考，具体文献需通过学术数据库查询)：
---
1. **文献名称**: *"CDKN2B methylation correlates with immune infiltration in acute myeloid leukemia"*
**作者**: Kim J. et al. (2018)
**摘要**: 研究通过甲基化特异性PCR和CDKN2B抗体免疫印迹，发现CDKN2B启动子高甲基化与AML患者肿瘤微环境中免疫细胞浸润减少相关，提示其表观遗传调控在白血病进展中的作用。
2. **文献名称**: *"p15INK4B expression loss in solid tumors: An immunohistochemical analysis"*
**作者**: Smith R. et al. (2020)
**摘要**: 使用抗CDKN2B(p15)抗体对多种实体瘤样本进行免疫组化分析，发现CDKN2B蛋白表达缺失与肿瘤分化程度低及预后不良显著相关，支持其作为抑癌基因的临床意义。
3. **文献名称**: *"CDKN2B regulates vascular smooth muscle cell senescence in atherosclerosis"*
**作者**: Zhang Y. et al. (2019)
**摘要**: 通过Western blot和免疫荧光(CDKN2B抗体)证实，动脉粥样硬化斑块中CDKN2B表达上调促进血管平滑肌细胞衰老，可能成为治疗靶点。
4. **文献名称**: *"Antibody-based detection of CDKN2B variants in neurodegenerative disorders"*
**作者**: Brown K. et al. (2021)
**摘要**: 开发了一种高特异性CDKN2B抗体，用于ELISA和脑组织染色，发现阿尔茨海默病患者脑脊液中CDKN2B剪切变体异常积累，提示其与神经退行性病变的潜在关联。
---
**注**：以上文献为示例，实际引用时请通过PubMed、Web of Science等平台检索真实研究，并核对作者、年份及摘要准确性。
The CDKN2B antibody is a key tool for studying the cyclin-dependent kinase inhibitor 2B (CDKN2B), a protein encoded by the *CDKN2B* gene located on chromosome 9p21.3. CDKN2B, also known as p15INK4B, belongs to the INK4 family of cell cycle regulators and inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), thereby blocking G1-to-S phase progression and promoting cell cycle arrest. This tumor suppressor is often epigenetically silenced or deleted in cancers, including gliomas, leukemias, and melanomas, contributing to uncontrolled proliferation. Its expression is also modulated by TGF-β signaling in growth inhibition contexts.
CDKN2B antibodies are widely used in research to detect protein expression via techniques like Western blotting, immunohistochemistry (IHC), and flow cytometry. They help investigate CDKN2B's role in diseases, such as its downregulation in tumorigenesis or its association with cardiovascular and aging-related disorders via genetic susceptibility loci. Validating antibody specificity is critical, as CDKN2B shares homology with other INK4 proteins (e.g., p16INK4A). High-quality antibodies enable studies on CDKN2B's interaction partners, post-translational modifications, and regulatory mechanisms. Clinically, CDKN2B antibodies may aid in diagnosing malignancies with 9p21 deletions or evaluating epigenetic therapies targeting DNA methylation. Overall, these antibodies are essential for unraveling CDKN2B's pathophysiological roles and therapeutic potential.
×
